Huya’s Foreign Clinical Advisory Team Includes Topol, Kowey
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Huya Bioscience has established a foreign clinical advisory team to collaborate with Huya's Chinese partners on clinical trials in China and the U.S. for the anti-arrhythmic compound HBI-3000 (sulcardine sulphate), the San Diego company announced March 3
You may also be interested in...
Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News
San Diego-based Huya Bioscience partners with Chinese research institutions and companies to identify preclinical and clinical-stage compounds, including traditional Chinese medicines to license for ex-China development. CEO Mireille Gingras recently spoke with PharmAsia News about Huya's partnership efforts in China. Prior to founding Huya, Gingras was founder and chief operating officer of MIR3, a software company developing online treatment programs for neuro-addictive diseases.
Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News
San Diego-based Huya Bioscience partners with Chinese research institutions and companies to identify preclinical and clinical-stage compounds, including traditional Chinese medicines to license for ex-China development. CEO Mireille Gingras recently spoke with PharmAsia News about Huya's partnership efforts in China. Prior to founding Huya, Gingras was founder and chief operating officer of MIR3, a software company developing online treatment programs for neuro-addictive diseases.
Organon Makes Deal With Huya For Access To Chinese Drugs
Organon has signed a collaborative deal with Huya Bioscience, a San Diego-based company that promises to link the Dutch drug maker with the owners of new compounds being developed in China